Literature DB >> 17942737

Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia.

Daniel J Lodge1, Anthony A Grace.   

Abstract

Evidence supports a dysregulation of subcortical dopamine (DA) system function as a common etiology of psychosis; however, the factors responsible for this aberrant DA system responsivity have not been delineated. Here, we demonstrate in an animal model of schizophrenia that a pathologically enhanced drive from the ventral hippocampus (vHipp) can result in aberrant dopamine neuron signaling. Adult rats in which development was disrupted by prenatal methylazoxymethanol acetate (MAM) administration display a significantly greater number of spontaneously firing ventral tegmental DA neurons. This appears to be a consequence of excessive hippocampal activity because, in MAM-treated rats, vHipp inactivation completely reversed the elevated DA neuron population activity and also normalized the augmented amphetamine-induced locomotor behavior. These data provide a direct link between hippocampal dysfunction and the hyper-responsivity of the DA system that is believed to underlie the augmented response to amphetamine in animal models and psychosis in schizophrenia patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942737      PMCID: PMC6673030          DOI: 10.1523/JNEUROSCI.2847-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  217 in total

Review 1.  Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?

Authors:  John Lisman
Journal:  Curr Opin Neurobiol       Date:  2011-11-11       Impact factor: 6.627

Review 2.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

3.  NMDAR antagonist action in thalamus imposes δ oscillations on the hippocampus.

Authors:  Yuchun Zhang; Takashi Yoshida; Donald B Katz; John E Lisman
Journal:  J Neurophysiol       Date:  2012-03-14       Impact factor: 2.714

Review 4.  Developmental pathology, dopamine, stress and schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Int J Dev Neurosci       Date:  2010-08-19       Impact factor: 2.457

Review 5.  Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases.

Authors:  Ashok K Shetty; Adrian Bates
Journal:  Brain Res       Date:  2015-09-28       Impact factor: 3.252

6.  Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Authors:  Ming Teng Koh; Yi Shao; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Schizophr Res       Date:  2017-06-17       Impact factor: 4.939

Review 7.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

8.  Uncovering the role of the nucleus accumbens in schizophrenia: A postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters.

Authors:  Lesley A McCollum; Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2015-09-18       Impact factor: 4.939

9.  An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia.

Authors:  Li Chen; Stephanie M Perez; Daniel J Lodge
Journal:  Dev Neurobiol       Date:  2014-03-03       Impact factor: 3.964

10.  Female rats are resistant to the long-lasting neurobehavioral changes induced by adolescent stress exposure.

Authors:  Katharina Klinger; Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Eur Neuropsychopharmacol       Date:  2019-07-29       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.